Denmark · Delayed Price · Currency is DKK Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of DKK 108.35 billion. The enterprise value is 132.32 billion.
| Market Cap | 108.35B |
| Enterprise Value | 132.32B |
Important Dates
The last earnings date was Friday, February 6, 2026.
| Earnings Date | Feb 6, 2026 |
| Ex-Dividend Date | Dec 5, 2025 |
Share Statistics
Coloplast has 225.17 million shares outstanding. The number of shares has increased by 0.17% in one year.
| Current Share Class | 207.17M |
| Shares Outstanding | 225.17M |
| Shares Change (YoY) | +0.17% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | 5.32% |
| Owned by Institutions (%) | 20.77% |
| Float | 143.39M |
Valuation Ratios
The trailing PE ratio is 27.19 and the forward PE ratio is 18.73. Coloplast's PEG ratio is 1.38.
| PE Ratio | 27.19 |
| Forward PE | 18.73 |
| PS Ratio | 3.88 |
| PB Ratio | 7.85 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.80 |
| P/OCF Ratio | 15.77 |
| PEG Ratio | 1.38 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.91, with an EV/FCF ratio of 24.19.
| EV / Earnings | 33.17 |
| EV / Sales | 4.74 |
| EV / EBITDA | 14.91 |
| EV / EBIT | 17.28 |
| EV / FCF | 24.19 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 1.82.
| Current Ratio | 1.30 |
| Quick Ratio | 0.76 |
| Debt / Equity | 1.82 |
| Debt / EBITDA | 2.83 |
| Debt / FCF | 4.59 |
| Interest Coverage | 10.74 |
Financial Efficiency
Return on equity (ROE) is 27.26% and return on invested capital (ROIC) is 13.08%.
| Return on Equity (ROE) | 27.26% |
| Return on Assets (ROA) | 9.85% |
| Return on Invested Capital (ROIC) | 13.08% |
| Return on Capital Employed (ROCE) | 18.74% |
| Weighted Average Cost of Capital (WACC) | 6.44% |
| Revenue Per Employee | 1.64M |
| Profits Per Employee | 234,882 |
| Employee Count | 16,983 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.38 |
Taxes
In the past 12 months, Coloplast has paid 2.19 billion in taxes.
| Income Tax | 2.19B |
| Effective Tax Rate | 35.44% |
Stock Price Statistics
The stock price has decreased by -37.39% in the last 52 weeks. The beta is 0.59, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -37.39% |
| 50-Day Moving Average | 529.13 |
| 200-Day Moving Average | 583.55 |
| Relative Strength Index (RSI) | 39.60 |
| Average Volume (20 Days) | 340,548 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of DKK 27.89 billion and earned 3.99 billion in profits. Earnings per share was 17.70.
| Revenue | 27.89B |
| Gross Profit | 18.93B |
| Operating Income | 7.66B |
| Pretax Income | 6.18B |
| Net Income | 3.99B |
| EBITDA | 8.58B |
| EBIT | 7.66B |
| Earnings Per Share (EPS) | 17.70 |
Balance Sheet
The company has 1.13 billion in cash and 25.10 billion in debt, with a net cash position of -23.97 billion or -106.46 per share.
| Cash & Cash Equivalents | 1.13B |
| Total Debt | 25.10B |
| Net Cash | -23.97B |
| Net Cash Per Share | -106.46 |
| Equity (Book Value) | 13.80B |
| Book Value Per Share | 61.31 |
| Working Capital | 2.37B |
Cash Flow
In the last 12 months, operating cash flow was 6.87 billion and capital expenditures -1.40 billion, giving a free cash flow of 5.47 billion.
| Operating Cash Flow | 6.87B |
| Capital Expenditures | -1.40B |
| Free Cash Flow | 5.47B |
| FCF Per Share | 24.30 |
Margins
Gross margin is 67.87%, with operating and profit margins of 27.46% and 14.30%.
| Gross Margin | 67.87% |
| Operating Margin | 27.46% |
| Pretax Margin | 22.15% |
| Profit Margin | 14.30% |
| EBITDA Margin | 30.78% |
| EBIT Margin | 27.46% |
| FCF Margin | 19.62% |
Dividends & Yields
This stock pays an annual dividend of 23.00, which amounts to a dividend yield of 4.78%.
| Dividend Per Share | 23.00 |
| Dividend Yield | 4.78% |
| Dividend Growth (YoY) | 4.55% |
| Years of Dividend Growth | 17 |
| Payout Ratio | 129.96% |
| Buyback Yield | -0.17% |
| Shareholder Yield | 4.60% |
| Earnings Yield | 3.68% |
| FCF Yield | 5.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 19, 2012. It was a forward split with a ratio of 5.
| Last Split Date | Dec 19, 2012 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Coloplast has an Altman Z-Score of 4.11 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.11 |
| Piotroski F-Score | 7 |